{"log_id": 4992283485244271126, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 0.011362, "average": 0.962954, "min": 0.363486}, "location": {"width": 1243, "top": 132, "height": 59, "left": 237}, "words": "通过治疗药物监测采指导后续的药剂量(参见【用法用】“治疗药物测”)。必要时可以间隔2"}, {"probability": {"variance": 0.015553, "average": 0.897111, "min": 0.570549}, "location": {"width": 1124, "top": 189, "height": 52, "left": 185}, "words": "周后调整剂量以达到谷浓度5-15gml(参见【月法用量】“剂量调察和“治疗药勿监测”)"}, {"probability": {"variance": 0.013642, "average": 0.945333, "min": 0.409398}, "location": {"width": 934, "top": 244, "height": 50, "left": 235}, "words": "持续治疗直至疾病进或出现不可耐受的毒性。尚不清楚治疗的最佳持续间"}, {"probability": {"variance": 0.012129, "average": 0.934502, "min": 0.695101}, "location": {"width": 166, "top": 299, "height": 34, "left": 182}, "words": "治疗药物监测"}, {"probability": {"variance": 0.022997, "average": 0.921901, "min": 0.383221}, "location": {"width": 1238, "top": 354, "height": 54, "left": 237}, "words": "对所有患者都应进行常规的依维莫司全血谷浓度监测。如果可能,在治疗期间的治疗药物监测中使"}, {"probability": {"variance": 0.030773, "average": 0.906339, "min": 0.362129}, "location": {"width": 338, "top": 409, "height": 36, "left": 180}, "words": "用相同的分析方法实验室"}, {"probability": {"variance": 0.016415, "average": 0.931154, "min": 0.438145}, "location": {"width": 1236, "top": 461, "height": 57, "left": 233}, "words": "应该在治疗开始后、或剂改变后、开始或整同时给药的CYP3A4或PgP诱导剂或抑制剂后、或肝"}, {"probability": {"variance": 0.019883, "average": 0.924377, "min": 0.42636}, "location": {"width": 1296, "top": 516, "height": 54, "left": 178}, "words": "功能改变后的大约2周,评估谷浓度,达到稳定剂量后,在治疗期间,对于表面积改变的患者应每36个"}, {"probability": {"variance": 0.008194, "average": 0.941593, "min": 0.665278}, "location": {"width": 928, "top": 571, "height": 50, "left": 178}, "words": "月监测一次谷浓度,对于体表面积稳定的患者应每-12个监测一次谷浓度"}, {"probability": {"variance": 0.033635, "average": 0.85918, "min": 0.442434}, "location": {"width": 425, "top": 626, "height": 45, "left": 230}, "words": "调整剂量以使谷浓度达到5-15ng/ml"}, {"probability": {"variance": 0.015735, "average": 0.912974, "min": 0.558978}, "location": {"width": 617, "top": 685, "height": 38, "left": 292}, "words": "如果谷浓度低于5niml按2.5mg的幅度增加口剂"}, {"probability": {"variance": 0.026317, "average": 0.893004, "min": 0.502554}, "location": {"width": 628, "top": 738, "height": 43, "left": 292}, "words": "如果谷浓度大于15ngml,2.5mg的幅度降低剂"}, {"probability": {"variance": 0.020785, "average": 0.921924, "min": 0.465415}, "location": {"width": 886, "top": 788, "height": 52, "left": 290}, "words": "如果接受最低可用规格剂量的思者需要下调剂量,则应每隔一日给药一次"}, {"probability": {"variance": 5.7e-05, "average": 0.987954, "min": 0.979536}, "location": {"width": 114, "top": 845, "height": 32, "left": 173}, "words": "剂量调整"}, {"probability": {"variance": 0.018173, "average": 0.877386, "min": 0.692568}, "location": {"width": 194, "top": 902, "height": 34, "left": 178}, "words": "不良反应的处理"}, {"probability": {"variance": 0.012786, "average": 0.93609, "min": 0.558831}, "location": {"width": 1241, "top": 957, "height": 50, "left": 226}, "words": "如果发严重和或不可耐受的不良反应,需要减少剂量和或暂色本治疗(参见【注意事项】)。将"}, {"probability": {"variance": 0.012011, "average": 0.948244, "min": 0.422152}, "location": {"width": 1296, "top": 1010, "height": 52, "left": 171}, "words": "木量降低大约50%。如果接受最低可用规格剂量的患者需要下调剂量,则应一日给药一次(参见表"}, {"probability": {"variance": 0.002583, "average": 0.851103, "min": 0.800278}, "location": {"width": 25, "top": 1067, "height": 29, "left": 176}, "words": "1)"}, {"probability": {"variance": 0.02427, "average": 0.882944, "min": 0.58643}, "location": {"width": 139, "top": 1120, "height": 34, "left": 173}, "words": "肾功能受损"}, {"probability": {"variance": 0.008379, "average": 0.97195, "min": 0.395959}, "location": {"width": 1238, "top": 1172, "height": 52, "left": 221}, "words": "在肾功能降低患者中没有进行本品临床研究。预期肾功能受损不会影响药物暴露,肾功能受损患者中"}, {"probability": {"variance": 0.016003, "average": 0.918916, "min": 0.520298}, "location": {"width": 594, "top": 1229, "height": 41, "left": 169}, "words": "不推荐调整依维莫司剂量(参见【药代动力学]"}, {"probability": {"variance": 0, "average": 0.87194, "min": 0.87194}, "location": {"width": 194, "top": 1245, "height": 54, "left": 964}, "words": "瘦"}, {"probability": {"variance": 0.009819, "average": 0.897747, "min": 0.713854}, "location": {"width": 139, "top": 1286, "height": 32, "left": 169}, "words": "肝功能受损"}, {"probability": {"variance": 0.013534, "average": 0.923667, "min": 0.513019}, "location": {"width": 1238, "top": 1339, "height": 50, "left": 221}, "words": "对于重度肝功能受损(Chld- Pugh C级)的管膜下巨胞星形细胞患者,本品的起始剂量需降低"}, {"probability": {"variance": 0.048778, "average": 0.826369, "min": 0.187101}, "location": {"width": 1229, "top": 1392, "height": 54, "left": 217}, "words": "大约5参见用法用量】“推荐剂量”对子轻度( chilk-pugh A级)或中( hild-pugh B级)"}, {"probability": {"variance": 0.01145, "average": 0.944962, "min": 0.461584}, "location": {"width": 1241, "top": 1449, "height": 50, "left": 217}, "words": "肝功能受损的室管膜下巨细胞星形细胞瘤患者,可能无需调整推荐起始剂,但是后续给药应基于治"}, {"probability": {"variance": 0.033394, "average": 0.844602, "min": 0.59495}, "location": {"width": 144, "top": 1504, "height": 34, "left": 217}, "words": "疗药物监测"}, {"probability": {"variance": 0.017837, "average": 0.920974, "min": 0.407687}, "location": {"width": 1229, "top": 1558, "height": 50, "left": 217}, "words": "应在治疗开始后,量改变后,成肝功能变后的大约2周,评估依维莫谷浓度参见【用法用量"}, {"probability": {"variance": 0.020205, "average": 0.940887, "min": 0.461204}, "location": {"width": 404, "top": 1616, "height": 34, "left": 242}, "words": "推荐剂量”“治疗药物监测”)"}, {"probability": {"variance": 0.03066, "average": 0.839485, "min": 0.465291}, "location": {"width": 452, "top": 1673, "height": 32, "left": 162}, "words": "CF3A网楼蛋点(PgP)抑制剂"}, {"probability": {"variance": 0.023819, "average": 0.864258, "min": 0.376219}, "location": {"width": 1216, "top": 1723, "height": 48, "left": 214}, "words": "使用品的者,避免同时使用CYP3A4强效抑制剂(如,酮康唑,于唑、克霉素、阿扎那"}, {"probability": {"variance": 0.02976, "average": 0.887934, "min": 0.362729}, "location": {"width": 1291, "top": 1776, "height": 48, "left": 160}, "words": "法唑削、沙韦、泰利霉素、利托那、地那韦、杂非韦、伏康唑)(参见【注意事项】“药吻"}, {"probability": {"variance": 0.026043, "average": 0.918637, "min": 0.421491}, "location": {"width": 850, "top": 1831, "height": 45, "left": 155}, "words": "互作用”和药物互作用】“可升高依莫司血药浓度的药物”"}, {"probability": {"variance": 0.016482, "average": 0.933897, "min": 0.458878}, "location": {"width": 1225, "top": 1888, "height": 48, "left": 210}, "words": "对于需要使用中效CYP3A和或PgP抑制剂(例如,氨普那书、山那帝、阿瑞匹垣、红霉素、氟康唑"}, {"probability": {"variance": 0.04718, "average": 0.854821, "min": 0.412455}, "location": {"width": 356, "top": 1945, "height": 34, "left": 157}, "words": "维拉米,地尔硫)的患"}, {"probability": {"variance": 0.019211, "average": 0.925058, "min": 0.403076}, "location": {"width": 1238, "top": 1997, "height": 52, "left": 208}, "words": "将本品剂这降低大约50%,妇接受最低可用规格剂量的患者需要下调剂,则应每一一给药一次(参"}, {"probability": {"variance": 0.013616, "average": 0.901619, "min": 0.564151}, "location": {"width": 377, "top": 2055, "height": 41, "left": 208}, "words": "见【用法用量】“推荐剂”)"}], "language": 3}